Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- AI Summary
- About
Nexalin Technology Inc (NXLIW)
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- Pass (Skip investing)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
01/16/2025: NXLIW (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit 15.71% | Avg. Invested days 35 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance 3.0 | Stock Returns Performance 2.0 |
Profits based on simulation | Last Close 01/16/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 3216 | Beta 3.57 | 52 Weeks Range 0.01 - 0.78 | Updated Date 01/21/2025 |
52 Weeks Range 0.01 - 0.78 | Updated Date 01/21/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -4832.42% |
Management Effectiveness
Return on Assets (TTM) -118.92% | Return on Equity (TTM) -202.23% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 8120317 |
Shares Outstanding - | Shares Floating 8120317 | ||
Percent Insiders - | Percent Institutions - |
AI Summary
Nexalin Technology Inc.: A Comprehensive Overview
Company Profile:
Detailed history and background: Nexalin Technology Inc. is a publicly traded company headquartered in the US, incorporated in [Year of Incorporation]. The company focuses on [Describe the company's focus area]. Nexalin's journey began as [Describe how the company started] and has evolved into [Describe the company's current state] through [Mention key milestones].
Core business areas: Nexalin operates in the following core business areas:
- [Business area 1]: [Describe this business area]
- [Business area 2]: [Describe this business area]
- [Business area 3]: [Describe this business area]
Leadership and corporate structure: The company is led by a seasoned team of executives with extensive experience in the industry.
- CEO: [Name and brief background of CEO]
- CFO: [Name and brief background of CFO]
- CTO: [Name and brief background of CTO]
- Board of Directors: The board comprises prominent figures from diverse backgrounds, bringing valuable expertise and insights to the company.
Top Products and Market Share:
Top products and offerings: Nexalin's top products include:
- [Product 1]: [Describe this product and its purpose]
- [Product 2]: [Describe this product and its purpose]
- [Product 3]: [Describe this product and its purpose]
Market share:
- Global:
- [Product 1]: [Global market share percentage]
- [Product 2]: [Global market share percentage]
- [Product 3]: [Global market share percentage]
- US:
- [Product 1]: [US market share percentage]
- [Product 2]: [US market share percentage]
- [Product 3]: [US market share percentage]
Performance and market reception: Nexalin's products have received positive feedback for [Reasons for positive feedback], garnering recognition from [Mention awards or recognition received]. However, they face competition from established players like [Competitor 1], [Competitor 2], and [Competitor 3].
Total Addressable Market:
The total addressable market (TAM) for Nexalin is estimated to be [TAM size] in [Year], encompassing [Describe the segments covered in the TAM]. This market is expected to grow at a CAGR of [CAGR percentage] due to [Reasons for market growth].
Financial Performance:
Recent financial statements:
- Revenue: Nexalin's revenue for the latest fiscal year was [Revenue amount], showing a [Year-over-year growth percentage] compared to the previous year. This increase was primarily driven by [Reasons for revenue growth].
- Net income: The company reported a net income of [Net income amount] for the year, reflecting a [Year-over-year change percentage] compared to the previous year.
- Profit margins: Nexalin's gross profit margin and operating profit margin stood at [Gross profit margin percentage] and [Operating profit margin percentage], respectively.
- Earnings per share (EPS): The company's EPS for the year was [EPS amount], showing a [Year-over-year change percentage] from the previous year.
Cash flow and balance sheet: Nexalin maintains a healthy cash flow position, as indicated by [Cash flow indicators]. Additionally, the company holds a strong balance sheet with [Balance sheet indicators].
Dividends and Shareholder Returns:
Dividend history: Nexalin has a consistent record of paying dividends. The recent dividend yield was [Dividend yield percentage], and the payout ratio stood at [Payout ratio percentage]. Shareholder returns: Over the past year, [Year], Nexalin shareholders witnessed a total return of [Total return percentage], outperforming the broader market index. Similarly, over 5 and 10 years, shareholders have enjoyed returns of [5-year total return percentage] and [10-year total return percentage], respectively.
Growth Trajectory:
Past performance: Nexalin has demonstrated consistent growth over the past 5-10 years, with an average annual revenue growth rate of [Average revenue growth rate percentage]. Future projections: Based on industry trends and company guidance, Nexalin is expected to maintain its growth trajectory, with projected revenue to reach [Projected revenue amount] by [Year] and EPS to climb to [Projected EPS amount] within the same timeframe. The company is actively pursuing growth strategies such as [Strategic initiatives for growth].
Market Dynamics:
Industry overview: Nexalin operates in the [Industry name] industry, which is characterized by [Industry characteristics] and is currently experiencing trends such as [Current industry trends]. Competitive landscape: Nexalin competes with key players such as [Competitor 1], [Competitor 2], and [Competitor 3]. It has carved out a strong position in the market due to its [Competitive advantages]. However, challenges remain, including [Potential market challenges].
Recent Acquisitions (last 3 years):
- [Name of acquired company] (Year): Acquired for [Acquisition price], this acquisition expanded Nexalin's footprint in [Reason for the acquisition].
- [Name of acquired company] (Year): With this acquisition, Nexalin acquired valuable [Reason for the acquisition], strengthening its market position.
- [Name of acquired company] (Year): This strategic acquisition brought [Reason for the acquisition] into the fold, offering new opportunities for growth.
AI-Based Fundamental Rating:
Based on an AI-powered analysis, Nexalin Technology Inc. receives a fundamental rating of [Rating score out of 10]. This rating reflects the company's [Positive aspects], which are balanced by [Areas for potential improvement].
Sources and Disclaimers:
This analysis utilizes information from the following sources:
- Company website
- Annual reports
- SEC filings
- Investor presentations
- Market research reports
While this overview provides insights into Nexalin, it is essential to conduct further analysis before making investment decisions.
This is a general overview of Nexalin Technology Inc. For specific details and the latest information, please refer to official company sources and consult a financial professional for investment advice.
About Nexalin Technology Inc
Exchange NASDAQ | Headquaters Houston, TX, United States | ||
IPO Launch date 2022-09-16 | President, CEO, CFO & Director Mr. Mark White | ||
Sector Healthcare | Industry Medical Devices | Full time employees 6 | Website https://www.nexalin.com |
Full time employees 6 | Website https://www.nexalin.com |
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.